FAM3B has been suggested to play important roles in the progression of many cancers, such as gastric, oral, colon and prostate cancer. However, little is known about the role of FAM3B in human esophageal squamous cell carcinoma (ESCC). In the present study, we found that FAM3B expression was higher in ESCC tissues than in adjacent normal tissues. Using quantitative real-time polymerase chain reaction, we found similar results in cell lines. FAM3B expression was significantly related to T/ TNM stage. Importantly, Kaplan-Meier analysis revealed that a high expression level of FAM3B predicted a poor outcome for ESCC patients. Overexpression of FAM3B inhibits ESCC cell death, increases oesophageal tumour growth in xenografted nude mice, and promotes ESCC cell migration and invasion. Further studies confirmed that FAM3B regulates the AKT-MDM2-p53 pathway and two core epithelial-tomesenchymal transition process markers, Snail and E-cadherin. Our results provide new insights into the role of FAM3B in the progression of ESCC and suggest that FAM3B may be a promising molecular target and diagnostic marker for ESCC.
| INTRODUCTION
Esophageal squamous cell carcinoma (ESCC) is the leading cause of cancer death in China. [1] [2] [3] According to the 2015 Chinese Cancer
Statistics, the morbidity of oesophageal cancer ranked 5th and its mortality ranked 4th among all kinds of malignant tumours. 4 Much effort has focused on improving tumour resectability and long-term locoregional control, but oesophageal cancer is still characterized by poor 5-year overall survival (OS), which rarely exceeds 40%. 5, 6 In addition to advances in surgical techniques and multimodal therapies to improve survival, research in the past decade has produced effective molecular targeted treatments for cancer therapy. 7, 8 Compared with lung cancer and colorectal cancer, the current targeted treatment for oesophageal carcinoma is still at the grouping stage, and no definite sensitive molecular markers and mechanisms have been identified. [8] [9] [10] Family with sequence similarity 3 (FAM3) is a cytokine-like gene family identified in 2002 through computational genomic searching for novel cytokines using structure-based homology methods. This
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family includes four genes: FAM3A, FAM3B, FAM3C and FAM3D. 11 Over the past decade, intensive studies have suggested that members of the FAM3 gene family may play an important role in the development of a variety of major diseases, including diabetes and cancer. [12] [13] [14] [15] Of the four family members, FAM3B has been studied the most. 16 FAM3B (also called PANDER) was originally identified in the endocrine pancreas and is also expressed in the small intestine, stomach and colon. In addition to identifying its role in glycolipid metabolism, research on FAM3B focuses on its biological role in tumour progression. In 2008, Huang et al 17 first reported that the expression level of FAM3B was lower in human gastric cancer tissues than in adjacent normal tissues and that its lower mRNA level was associated with deeper tumour invasion of gastric cancer tissues. These findings suggested that abnormal expression of FAM3B might be involved in cancer initiation and progression. Since then, the regulatory role of FAM3B in the progression of other tumours, including oral squamous cell carcinoma and colon and prostate cancer, have been reported. [18] [19] [20] In addition, another FAM3 family member, FAM3C, was reported to be closely involved in the development of oesophageal cancer. 21 These studies have increased interest in exploring whether FAM3B also plays an important role in the progression of oesophageal cancer.
In 
| Cell cycle assays
In cell cycle assay, cells were first transfected for 48 hours and then fixed with 75% ethanol and stained with 500 μL of PBS containing 50 μg/mL propidium iodide and 0.1% TritonX-100 in the dark at 4°C.
All samples were analysed by flow cytometry, and the data were processed using Cell Quest software. The apoptosis rates of ESCC cell lines were measured by flow cytometry 48 hours after transfection. DNA fragmentation assays were conducted using AnnexinV-FITC Apoptosis Detection Kit (BD Biosciences) according to the manufacturer's protocol.
| Protein extraction and Western blot analysis
Cells were lysed in ice-cold lysis buffer containing fresh protease inhibitor. Cellular lysate extracts were scraped from the wells, collected in Eppendorf tubes, and centrifuged at 12 000 g for 10 minutes at 4°C. The total cell proteins were obtained and quantified using a NanoDrop TM 2000/2000c spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Equal amounts of proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the separate proteins were transferred to a PVDF membrane.
The membrane was blocked with 5% fat-free milk at 37°C for 1 hour and then incubated with the homologous primary antibodies (Abcam) overnight at 4°C. The membranes were rinsed, incubated in peroxidase-conjugated secondary antibody at 37°C for 30 minutes, and analysed using a chemiluminescence system (Amersham Biosciences, UK). The stained bands were scanned and filed, and the pixel intensity was analysed using Alpha processing software (Alpha Innotech, Chengdu, china).
| Lentivirus packaging and transduction
The recombinant vectors were first constructed by cloning full-length human FAM3B cDNA into the pEB-GFP (T2A) PURO vector using a Clon Express II One
Step cloning kit (Vazyme, Nanjing, China)
according to the manufacturer's protocol and then transformed into 
| Tumour formation in nude mice
Animal experiments were conducted in the State Key Laboratory of After 4 weeks, the mice were sacrificed and tumour tissues were removed. The protein was extracted from the tumour tissues and used for Western blot analysis.
| Plasmid construction and RNA interference
A plasmid expressing FAM3B was purchased from FitGene (Guangzhou, China). The siRNA sequence targeting human FAM3B was designed and synthesized by Ribobio (Guangzhou, China). An empty plasmid or scrambled siRNA served as a NC. TE-1 and 
| Statistical analyses
Each sample was assayed in triplicate, and each experiment was repeated three times. Chi-squared test or two-way ANOVA was used to compare the means of independent samples. Differences between FAM3B levels in tumour tissues and adjacent non-tumour tissues were analysed using the Wilcoxon matched-pairs test. The survival rates in relation to FAM3B expression were estimated using the Kaplan-Meier method, and the log-rank test was used to compare Kaplan-Meier survival curves. Statistical analyses were performed using SPSS for Windows v. 16.0 (SPSS Inc, Chicago, IL, USA).
P-values <0.05 were considered to be significant. 
| FAM3B expression is associated with ESCC clinicopathological parameters and prognosis
We explored further whether FAM3B protein expression was significantly related to the clinicopathological parameters of ESCC patients.
FAM3B expression was not significantly related to gender, age, differentiation, or lymph node metastasis. By contrast, increased expression of FAM3B in ESCC was significantly associated with invasion and TNM stage (P = 0.011 and 0.003, respectively; Table 3 ).
The FAM3B expression measured by immunohistochemistry was used to classify ESCC patients into two groups: a high-expression group (20 patients) and low-expression group (20 patients). Their prognosis was measured as OS. The respective average survival and 5-year survival rates were 58 months and 45% for the low-expression group and 42 months and 15% for the high-expression group.
Kaplan-Meier survival analysis revealed that patients in the high-expression group had poorer OS than those in the low-expression group (P < 0.01; Figure 2C ).
| FAM3B promotes ESCC progression in vitro and in vivo
To assess the biological role of FAM3B in ESCC progression, we per- The colony-formation assay showed that FAM3B silencing signif- To explore further the effect of FAM3B in vivo, we established stably expressed FAM3B using ECA109 cell line, and FAM3B transfection efficiency was measured by Western blot ( Figure 7A ).
T A B L E 2 Clinicopathological features of ESCC patients
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ECA109 cells that stably overexpressed FAM3B were implanted into
the left armpit and control cells into the right armpit of nude mice.
Four weeks after injection, tumours were visible in both armpits of all five mice. As seen in Figure 7B and C, tumours removed from the left armpit were markedly larger in volume than those taken from the right side (P < 0.01), which suggested that FAM3B increased tumour growth in vivo mouse model.
| FAM3B promotes ESCC progression through regulation of the AKT-MDM2-p53 pathway and epithelial-mesenchymal transition
To examine whether the AKT-MDM2-p53 pathway and epithelial- 
| DISCUSSION
Although several molecular markers closely associated with tumour progression have been recognized, more sensitive markers are needed because of the poor prognosis of ESCC patients. FAM3B is expressed in many normal human tissues, including the pancreas, small intestine, stomach and oesophagus. Initially, FAM3B was confirmed to be a cytokine that triggers cell apoptosis and was therefore assumed to be a potential tumour marker. 
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The AKT-MDM2-p53 signalling axis has a profound effect on cell apoptosis. This signalling pathway is involved in the development and progression of many cancers, including prostate cancer, 27 bladder cancer, 28 ovarian cancer 29 and breast cancer. 30 However, the Cell cycle dysregulation is also a major factor affecting cancer cell growth. Of previous FAM3B-related studies, we found only one paper reporting that FAM3B inhibits the cell cycle progression of gastric cancer cells by up-regulation of p21. 42 To provide a better understanding of the molecular functions of FAM3B, we used flow cytometry to analyze the changes in the cell cycle in ECA109/TE-1 cells transfected with the FAM3B siRNA sequence. We found no significant difference (data not shown), which indicates that the mechanism through which FAM3B promotes ESCC progression is independent of cell cycle control. signalling pathway and the EMT, as proposed in Figure 9 . FAM3B may be a potential prognostic marker and molecular target for therapy in clinical treatment. These findings provide a basis for exploring further the molecular mechanisms underlying FAM3B-induced ESCC progression.
